Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders

Abstract: A class of substituted phenylpyrimidine compounds are disclosed which are potent inhibitors of the excitatory amino acid, glutamate. Such compounds are useful in the treatment or prevention of a range of CNS disorders including cerebral ischaemic damage and epilepsy.

Description: The present invention relates to .a class of pyrimidine compounds which are useful in the treatment of central nervous system (CNS) diseases and disorders such as the prevention of cerebral ischaemic damage, to pharmaceutical compositions containing them, to their use in; the treatment of such disorders, and to methods of preparing them. Glutamate is an excitatory amino acid which functions as a neurotransmitter. However, when its extracellular concentration is sufficiently high, glutamate acts as a powerful neurotoxin, capable of killing neurones in the central nervous system, (Rothman & Olney (1986) Prog.Brain.Res., 63 , 69). The neurotoxic effect of glutamate has been implicated in a number of central nervous system disorders and disease states including cerebral ischaemic damage, epilepsy and chronic neurodegenerative disorders, such as Alzheimer's disease, motor system disorders, and Huntington's chorea, (Meldrum Clinical Science (1985) 68 113-122 ). In addition, glutamate has been implicated in other neurological disorders such as manic depression, depression, schizophrenia, high pressure neurological syndrome, chronic pain, trigeminal neuralgia and migraine. In European Patent application No.21121 there is disclosed a group of 3,5-diamino-6-(substituted phenyl)-1,2,4-triazines which are active in the treatment of CNS disorders, for example in the treatment of epilepsy. One compound described in that application, 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine (lamotrigine), has been shown to inhibit the release of the excitatory amino acids, glutamate and aspartate, (Leach et al Epilepsia 27 , 490-497 1986, A.A.Miller et al New anticonvulsant drugs. Ed. Meldrum and Porter 165-177, 1987). The present inventors have now found that a series of substituted pyrimidine compounds, as defined in Formula I, are potent inhibitors of glutamate release; these compounds are useful in the treatment of the above mentioned-disorders and disease states of the central nervous system. The pyrimidine compounds of formula I are also inhibitors of aspartate release. Thus according to the first aspect of the present invention there is provided a pyrimidine of formula I: wherein, R 1 s N-methylpiperazinyl; R 2 is amino; R 3 is selected from trifluoromethyl, hydrogen, methyl, benzyloxymethyl, methoxymethyl and methylthiomethyl; R 4 is chloro; and at least one of R 5 , R 6 and R 7 is chloro, and the remainder of R 5 , R 6 and R 7 are selected from hydrogen and chloro in the case of R 5 and R 7 , and from hydrogen, chloro and nitro in the case of R 6 , except that R 6 is not hydrogen when R 1 is N-methylpiperazino, R 2 is amino, each of R 3 and R 6 is hydrogen and each of R 4 , R 5 and R 7 is chloro; R 9 is hydrogen; and pharmaceutically acceptable acid addition salts thereof. Certain pyrimidines of Formula (I) are chiral, and it will be appreciated that in these instances, Formula (I) encompasses both the racemic mixture and the individual enantiomers of such compounds. R 5 , R 6 and R 7 are preferably selected from hydrogen and chloro. It is a preferred feature of Formula (I) that at least one of R 5 and R 7 are chloro. In particular, it is preferred that both R 5 and R 7 are chloro. Such compounds are highly potent inhibitors of glutamate release. The present invention also provides a subclass of pyrimidines of Formula (I), which whilst being potent inhibitors of glutamate release show only weak (i.e. having an IC 50 of >20µm) or insignificant inhibitory effects on the enzyme dihydrofolate reductase. Accordingly, in a preferred embodiment of the present invention there are provided pyrimidines of Formula (I) where R 1 to R 8 are hereinbefore defined with the proviso that when R 7 is chloro, then R 3 is hydrogen, methyl or methoxymethyl and/or R 6 is nitro; or with the proviso that when R 6 is chloro then R 4 is chloro, and R 3 is hydrogen, methoxymethyl, methyl or halo. Preferred compounds of the present invention are: 2-(4-methylpiperazin-1-yl)-4-amino-5-(2,3,5,-trichlorophenyl)-6-trifluoromethylpyrimidine; 2-(4-methylpiperazin-1-yl)-4-amino-5-(2,3,5-trichlorophenyl)-6-methylpyrimidine; 2-(4-methylpiperazin-1-yl)-4-amino-5-(2,4-dichlorophenyl)pyrimidine; and pharmaceutically acceptable acid addition salts thereof. In a preferred embodiment the present invention also provides a pharmaceutically acceptable acid addition salt of a pyrimidine as described above. The compounds of the invention may.be used in the treatment or prophylaxis of acute and chronic disorders of the mammalian central nervous system. The acute condition comprises cerebral ischaemia which may arise from a variety of causes including stroke, cardiac arrest, bypass surgery, neonatal anoxia and hypoglycaemia; also physical injury or trauma of the spinal cord or brain. Chronic neurodegenerative disorders which may be treated include Alzheimer's disease, Huntington's chorea, Olivoponteocerebrellar atrophy and motor system disorders. Other neurological conditions which may be treated with a compound of the invention include depression, manic depression, schizophrenia, chronic pain, epilepsy, trigeminal neuralgia and migraine. A compound of the invention can be used in the treatment of a disease or disorder.of the central nervous system of a mammal in which extracellular-glutamate is implicated. A mammal predisposed to or having neurotoxic extracellular glutamate levels of the central nervous system can thus be treated. Certain substituted phenylpyrimidines of the present invention are known in the art as having antimalarial activity. See for example Brit.J.Pharmacol. 6, 185-200 (1951) ; JACS, 73, 3763-70, (1951) . Other phenylpyrimidines are know from Chem.Biol. Ptderidines, 463-468, (1982 ) and Pharmacotherap.Budesinsky, p.129-141, (1963), ed. Oldrich Hanc . Nonetheless, compounds of the present invention are novel and accordingly the present invention provides a pyrimidine of Formula (I) or an acid addition salt thereof wherein R 1 to R 9 are as hereindefined. Preferred novel compounds of the present invention include the following, the numbers referring to the Examples hereinafter appearing:- Example No. 1. 4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine 2. 4-Amino-6-methyl-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine 3. 2-N-methylpiperazinyl-4-amino-5-(2,4-dichlorophenyl)pyrimidine or an acid-addition salt thereof. Suitable acid addition salts of the compounds of Formula I include those formed with both organic or inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. Thus, preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, p -toluenesulphonic, benzenesulphonic and isethionic acids. These salts can be made by reacting the compound as the free base with the appropriate acid. While it is possible for the compounds of Formula I to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. The formulations of the present invention comprise a novel compound of Formula I, as above defined, or a pharmaceutically acceptable salt thereof together with one or more acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations include those suitable for oral, parenteral (including subcutaneous; intradermal, intramuscular and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon for example the condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste. A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Formulations for rectal administration may be presented as a suppository with the usual carriers such as cocoa butter or polyethylene glycol. Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia. Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient. It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents. Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of compound of the Formula I which is effective at such dosage or as a multiple of the same, for instance, units containing 5mg to 500mg, usually around 10mg to 250mg. The compounds of the Formula I are preferably used to treat CNS disorders or diseases by oral administration or injection (intraparenteral or subcutaneous). The precise amount of compound administered to a patient will be the responsibility of the attendant physician. However the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Thus for example when treating a patient with epilepsy the dose range is likely to be significantly lower than when treating a patient after stroke to alleviate cerebral ischaemic damage. Also the route of administration is likely to vary depending on the condition and its severity. The compounds of the Formula (I) may be administered orally or via injection at a dose of from 0.1 to 30mg/kg per day. The dose range for adult humans is generally from 8 to 2,400 mg/day and preferably 35 to 1,050 mg/day. As certain compounds of the Formula (I) are long acting, it may be advantageous to administer an.initial dose of 70 to 2,400 mg the first day then a lower dose of 20 to 1,200 mg on subsequent days. An example of such a long acting compounds is 4-amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine. Long acting compounds in the clinic are advantageous because they are easier to manage. In the chronic situation, they may be administered without infusion and there is the minimum of direct medical intervention; also in acute conditions, patient compliance is encouraged by minimising daily dosing. Conversely, short acting compounds permit the clinician to control the pharmacological effect of the compound with great precision, since such compounds will be cleared from the central nervous system rapidly. Compounds of the present invention may be made in any manner known to make analogous compounds known in the art (eg. JACS vol 73 (1951) 3763-70 ). The present invention also provides a process for the preparation of a compound of formula (I) or an acid addition salt thereof, which comprises the reaction of a compound of formula (II): wherein R 3 to R 8 are as hereinbefore defined, L is a leaving group, and Y is cyano with a compound or salt thereof of formula (III) : wherein R 1 is as hereindefined; isolating the compound of Formula (I) as the free base or as a pharmaceutically acceptable acid addition salt thereof; and optionally converting the base into a pharmaceutically acceptable acid addition salt thereof or into another pyrimidine of Formula (I) or an acid addition salt thereof. If it is required to make a compound of Formula (I) in which one of R 6 is nitro, this can be made from the corresponding compound of Formula (I) where R 6 is hydrogen by utilising standard nitration conditions, e.g. sulphuric acid and potassium nitrate, and then further converted by standard reduction means to the corresponding amino compound, e.g utilising PtO 2 , AcoH, H 2 . It will be appreciated that amino or halo compounds can be further converted to R 4 to R 8 as herewithin defined by standard interconversion, for example, via the diazonium salts. When R 3 is alkyl this may be converted into perhaloalkyl, or a halogenated,alkyl moiety by reaction with the appropriate halogen or N-halo succinimide (NXS) in a suitable solvent such as acetic acid. Where in the product of the above process R 3 is a group CH 2 OR where R is alkyl or arylalkyl this product may be converted to CH 2 X by reaction with HX (X = halo) in, for example acetic acid, and this further converted to the corresponding cyano compound, for example by treatment with sodium cyanide and DMF, or to fluoromethyl by treatment with for example cesium fluoride (CsF). Alternatively, the group CH 2 OR can be dealkylated to give the corresponding alcohol, for example with Me 3 SiI, and this further converted to fluoromethyl with diethylaminosulphur trifluoride (DAST). Where R 3 contains an alkylthio moiety, this can be oxidised to the corresponding sulphoxide and sulphone using for example MCPBA (metachlorperbenzoic acid). It will be appreciated that other interconversions may be effected as required by those skilled in the art using standard methodologies. Example of suitable leaving groups (L) include C 1-4 alkoxy, halo, anilino, morpholino, C 1-4 alkylamino, benzylamino, or alkylthio. Advantageously, R 1 is N -methylpiperazinyl. Preferably L is C 1 -C 4 alkoxy. Preferably the reaction of the compound of Formula (I) and (II) is carried out in a non-aqueous solvent, for example an alkanol, e.g. ethanol at elevated temperatures (e.g. between 50 to 110°C) in base, preferably an akanoxide, preferably under reflux using sodium ethoxide as the base. Compounds of Formula (II) may be made by methods known in the art (JACS supra) for example by the method of JACS, 1952, 74, 1310-1313 . In Formula (III) when R 1 is methyl piperazinyl these can be made by standard methods, for example by reaction of a known compound of Formula (III) where R 1 is N -methylpiperazine. This reaction preferably takes place at room temperature in water. Further provided by the present invention is a process for the preparation of a pyrimidine of Formula (I) which process comprises reacting a compound of Formula (V): wherein R 3 to R 8 and Y are as hereinbefore defined and R 10 and R 11 are both alkyl or together form a group -(CR 2 ) n - where R is hydrogen or alkyl, and n is an integer of from 2 to 4, with a compound of Formula (III) as defined above. Preferably the reaction is carried out in a non-aqueous solvent, e.g. ethanol, under reflux using sodium ethoxide as the base. Still further provided by the present invention is a pharmaceutical formulation comprising a pyrimidine of Formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carriers therefor. Preferably said a pharmaceutical formulation is suitable for oral administration and comprises a pyrimidine of Formula (I)as defined above or a pharmaceutically acceptable acid addition salt thereof and one or more carriers therefor. More preferably the present invention provides capsules or tablets suitable for oral administration, each containing a predetermined amount of a pyrimidine of Formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carriers therefor. The present invention further provides a pharmaceutical formulation suitable for parenteral administration comprising a pyrimidine of Formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carriers therefor. Preferably said pharmaceutical formulation suitable for parenteral administration is presented in unit-dose containers and comprises a pyrimidine of Formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carriers therefor. Compounds of Formula (I) may also be prepared from the corresponding dihydropyrimidine by utilising standard dehydrogenation conditions, (e.g. JCS, 1956, 1019). Such dihydropyrimidines can be prepared by the reaction of a compound of Formula (II) where R 3 to R 8 are as defined and L is hydrogen with a compound of Formula (III). In the Examples of the invention set forth below, the chemical and other abbreviations used are standard in the art and have these meanings:- NaBH 4 : sodium borohydride CHCl 3 : chloroform NaHCO 3 : sodium bicarbonate MgSO 4 : magnesium sulphate PBr 3 : phosphorus tribromide DMF : dimethylformamide KCN : potassium cyanide Et 2 O : diethyl ether NaOEt : sodium ethoxide EtOH : ethanol H 2 O 4 : sulphuric acid AcOH : acetic acid MeOH : methanol N 2 : nitrogen HCl : hydrochloric acid NaOH : sodium hydroxide SiO 2 : silica DMSO : dimethylsulphoxide Na : sodium DME : dimethoxyethane MeI : methyl iodide (iodomethane) EtOAc : ethyl acetate CH 2 Cl 2 : dichloromethane Et 3 N : triethylamine MeNH 2 : methylamine NH 4 OH : ammonium hydroxide SOCl 2 : thionyl chloride THF : tetrahydrofuran NaH : sodium hydride CCl 4 : carbon tetrachloride DHFR : dihydrofolate reductase PtO 2 : platinum oxide (Adams' catalyst) NXS : N-halo succinimide X 2 : halogen TFAA : trifluoroacetic anhydri de CsF : cesium fluoride Me 3 SiI : trimethylsilyliodide DAST : diethylaminosulphur trifluoride MCPBA : metachloroperbenzoic acid AIBN : α,α'-azoisobutyronitrile (2,2'-azobis(2-methylpropionitrile) Example 1 Preparation of 4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine 1. Preparation of N-methylpiperazinoformamidine hydriodide Thiourea (10.8g) was dissolved in acetone (250ml) at 50°C. Iodomethane (10ml) was added and the reaction was stirred at 50°C for 4 hours. After cooling, the solution was diluted with ether (1 litre) and the methiodide salt was filtered, washed with ether and dried in vacuo , 29.2g, 113-115°C. The methiodide salt (5g) was dissolved in water, (30ml) and N-methylpiperazine was added. The solution was stirred, with nitrogen bubbled through, at room temperature for 24 hours. The solution was concentrated in vacuo . The residue was slurried with ethanol, filtered and dried in vacuo , 4.98g, m.pt.230-242°C. 2. Preparation of 2,3,5-trichlorobenzylalcohol To a solution of 2,3,5-trichlorobenzaldehyde (Aldrich, 50gms) in ethanol (1.0L) at room temperature was added NaBH 4 (7.00gms) and the resulting mixture stirred for 3.5 hours. The reaction was quenched with water, and the solvent evaporated in vacuo before partitioning the residue between CHCl 3 and saturated NaHCO 3 solution. The organic phase was washed with brine, dried over MgSO 4 , filtered and the solvent evaporated in vacuo to leave a white solid. 43.00gms, mp. 90-93°C. 3. Preparation of 2,3,5-trichlorobenzyl bromide To a solution of the alcohol in benzene (400ml) under N 2 was added PBr 3 (126.58gms), and the mixture stirred at 55-60°C for 3.5 hours. After cooling, the mixture was poured onto crushed ice (2L) and the benzene layer separated. The aqueous phase was washed with benzene (x3) and the combined benzene extracts washed with saturated NaHCO 3 solution and water, dried over MgSO 4 , filtered and the solvent evaporated to leave a brownish liquid which solidified on standing, 37.53gms, mp. 40-42°C. 4. Preparation of 2,3,5-trichlorophenylacetonitrile The bromide was suspended in DMF (130ml)/ water (86.67ml) at 0°C and KCN(12.99gms) added in portions. After stirring at 30-35° for 3 hours, the suspension was diluted with water and extracted with Et 2 O. The combined ether extracts were washed with water, dried over MgSO 4 , filtered and the solvent evaporated in vacuo . Chromatography on silica gel eluting with hexane to 20% ether-hexane gave the desired product as a white solid, 18.52gms, mp. 60-62°C. 5. Preparation of 2-(2,3,5-trichlorophenyl)-4,4,4-trifluoro-3-oxobutyronitrile To a solution of NaOEt (from 1.04gms Na) in EtOH (60ml) at room temperature under N 2 was added the nitrile (8.40gms) followed by ethyl trifluoroacetate (6.57gms) and the mixture stirred at reflux for 5 hours. After cooling, the solvent was removed in vacuo and the residue dissolved in water. The aqueous phase was washed with Et 2 O (discarded), acidified with H 2 O 4 and extracted with Et 2 O. The combined Et 2 O extracts were washed with water, dried over MgSO 4 , filtered and the solvent evaporated in vacuo to leave an oil. This was triturated with petroleum ether, and the solid filtered off and dried. The solid was azeotroped with toluene (x5), 4.89gms, mp. 160-163°C. 6. Preparation of 2-(2,3,5-trichlorophenyl)-4,4,4-trifluoro-3-methoxybut-2-enonitrile To a solution of the trifluoromethyl ketone in Et 2 O (39.62ml) at room temperature was added diazomethane (from 8.55gms Diazald) in Et 2 O (79.62ml), and the resulting mixture left to stand at room temperature overnight. Excess diazomethane was then removed in vacuo into AcOH, and the residue was dissolved in Et 2 O, dried over MgSO 4 , filtered and the solvent evaporated in vacuo to leave a brownish oil, 5.20gms. 7. Preparation of 4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine To a solution of NaOEt (from 0.144g of Na) in EtOH (12.5ml) was added N-methylpiperazinoformamidine hydriodide (1.39g). After stirring for 10 minutes at room temperature a solution of the above intermediate (0.85g) in EtOH (2.5ml) was added and the resulting mixture was stirred at reflux for 4.5 hours After cooling, the suspension was filtered, and the filtrate was evaporated to dryness in vacuo . Chromatography on silica gel, eluting with CHCl 3 -4% MeOH/CHCl 3 , gave the desired product which was triturated with petroleum ether (b.p. 40-60°C) and dried in vacuo . 0.56g, m.pt 127-129°C. 8. 4-Amino-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine methanesulphonate The phenyl pyrimidine base (9.6g) was dissolved in absolute ethanol, cooled at 0°C, and methanesulphonic acid (2.14g, 1.62ml) was added. After stirring at room temperature for 2 hours, the solution was evaporated to dryness and the residue triturated with Et 2 O, filtered and dried in vacuo to leave a beige coloured solid. This was dissolved in water (500mls) and freeze-dried to leave 10.7g as a tan coloured solid. The methanesulphonate salt could be further purified by triturating with t BuOH (30ml), filtering, dissolving in water and again freeze drying to leave the title product as a off-white solid. 8.33g mp. 145-7°C. Example 2 Synthesis of 4-Amino-6-methyl-2-(4-methylpiperazin-1-yl)-5-(2,3,5-trichlorophenyl)pyrimidine To a solution of NaOEt (from 0.16g of sodium) in ethanol (15ml) was added N -methylpiperazinoformamidine hydriodide (1.6g). After stirring for 10 minutes the enol ether of Example 6.2 (0.82g) in ethanol (5ml) was added and the mixture was stirred at reflux for 5 hours. The mixture was left standing at room temperature overnight and then filtered. The filtrate was concentrated and the residue was purified by chromatography on SiO 2 gel, eluting with CHCl 3 to 4% MeOH/CHCl 3 to give the desired product, 0.31g, mp. 156-159°C. Example 3 2-(4-methylpiperazin-1-yl)-4-amino-5-(2,4-dichlorophenyl)pyrimidine A) A solution of 55.7g (0.4equiv) of S -methylisothiourea sulphate in 280ml of water was prepared and gently heated on a steam bath with stirring. Then 40g (0.4mol) of N -methyl-piperazine was slowly dripped into the solution while sweeping the flask out with nitrogen. The evolved gases were collected in several portions of a solution of 132g of mercuric chloride in 400ml of ethanol, which caused evolved methylmercaptan to be precipitated as methylmercuric chloride. After the addition of the N-methylpiperazine was complete, the reaction was continued until no more methylmercuric chloride precipitated. The reaction mixture was then concentrated in vacuo and chilled which caused the N-methyl-N'-amidinopiperazine sulphate to crystallise; 50.79g was collected. B). A mixture of 76.3g (0.356 mol) of α-formyl-2,4-dichlorophenyl-acetonitrile, 63.7g of isoamyl alcohol, 0.36g of p -toluenesulphonic acid, 895 ml of toluene, and 10 drops of concentrated sulphuric acid were heated under reflux for 20 hours in the presence of a Dean and Stark trap to remove water formed in the reaction. Then an equal portion of i-amyl alcohol and a few drops of sulphuric acid were added, and the reaction was heated for another 20 hours, until the theoretical amount of water had been collected. The solution was cooled. C) An 8.2g portion of sodium was dissolved in 500ml of absolute ethanol, and 50g of N -methyl- N '-amidinopiperazine sulphate was added. The mixture was allowed to stir for 10 minutes. This was then added to solution B. The mixture was refluxed with stirring for 6 hours, allowed to stand overnight and the solvent removed in vacuo . The residue was then extracted with dilute hydrochloric acid, which dissolved most of it. The solution was extracted three times with ether, followed by neutralization of the aqueous fraction, which precipitated a gum which solidified upon standing overnight; weight 30g. This was crystallised repeatedly from 50% ethanol with the aid of decolourising charcoal. Very slow cooling was required in order for crystals to be formed; mp. 137°C. Anal. Calcd for C 15 H 17 Cl 2 N 5 ; C, 53.27; H, 5.07; N, 20.71; Found C, 53.58; H, 5.14: N, 20.40. Preferred among the compounds of formula (I) is the pyrimidine of the foregoing Example 1, together with salts (in particular, pharmaceutically acceptable salts) thereof; this base has the following two-dimensional structure. Example 1 TABLE OF 1 H NMR DATA (δ) Example No. Solvent Assignment 1 CDCl 3 7.56(d,1H), 7.18(d,1H), 4.65-4.50 (br.s,2H), 3.88(t, 4H), 2.5(t,4H), 2.36(s,3H) 2 CDCl 3 7,51(d,1H), 7.17(d,1H), 4.40-4.22 (br.s,2H), 3.82 (t,4H), 2.48(t, 4H) , 2.34(s,3H), 2.0(s,3H) In the foregoing, the signals have been abbreviated as follows: s=singlet; d=doublet; dd=doublet of doúblets; t=triplet; q=quadruplet; m=multiplet; br.s=broad singlet; br.t=broad triplet. Pharmacological Activity Inhibition of Glutamate release and Inhibition of Rat Liver (DHFR) Compounds of Formula (I) were tested for their effect on veratrine-evoked release of glutamate from rat brain slices according to the protocol described in Epilepsia 27(5): 490-497, 1986 . The protocol for testing for inhibition of DHFR activity was a modification of that set out in Biochemical Pharmacology Vol.20 pp 561-574, 1971 . The results are given in Table 1, the IC 50 being the concentration of compound to cause 50% inhibition of (a) veratrine-evoked release of glutamate and (b) of DHFR enzyme activity. TABLE 1 Compound of Example No. IC 50 (µM) Glutamate Release (P95 limits) IC 50 (µM) Rat Liver DNFR (P95 limits) 1 1.18 (0.50-2.60) >100 2 4.80 (2.30-10.20) >100.00 3 ca. 10.00 >100.00 Toxicological Example The compound of Example 1 has been administered intravenously to groups of six male and six female Wistar rats once daily at dose levels of upto 15mg/kg/day. The no observsed effect dose was 2.5mg/kg/day. Pharmacutical Formulation Example Tablet: INGREDIENT A Compound of Example 1 150 mg) Lactose 200 mg) Maize Starch 50 mg) Polyvinylpyrrolidone 4 mg) Magnesium Stearate 4 mg) ) = contents per tablet. The drug was mixed with the lactose and starch and granulated with a solution of the polyvinylpyrrolidone in water. The resultant granules were dried, mixed with magnesium stearate and compressed to give tablets. B: INJECTION (I) The salt of the compound of Formula I was dissolved in sterile water for injection. INTRAVENOUS INJECTION FORMULATION (II) Active ingredient 0.20g Sterile, pyrogen-free phosphate buffer (pH9.0) to 10ml The compound of Example I as a salt is dissolved in most of the phosphate buffer at 35-40°C, then made up to volume and filtered through a sterile micropore filter into sterile 10ml glass vials (Type 1) which are sealed with sterile closures and overseals. In the following Examples, the active compound maybe any compound of formula (I) or pharmaceutically acceptable salt thereof. C: Capsule formulations Capsule Formulation A Formulation A may be prepared by admixing the ingredients and filling two-part hard gelatin capsules with the resulting mixture. mg/capsule (a) Active ingredient 250 (b) Lactose B.P. 143 (c) Sodium Starch Glycollate 25 (d) Magnesium Stearate 2 420 Capsule Formulation B mg/capsule (a) Active ingredient 250 (b) Macrogel 4000 8P 350 600 Capsules may be prepared by melting the Macrogel 4000 BP, dispersing the active ingredient in the melt, and filling two-part hard gelatin capsules therewith. Capsule Formulation B (Controlled release capsule) mg/capsule (a) Active ingredient 250 (b) Microcrystalline Cellulose 125 (c) Lactose BP 125 (d) Ethyl Cellulose 13 513 The controlled-release, capsule formulation may be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with ethyl cellulose (d) as a controlled-release membrane and filled into two-part hard gelatin capsules. Syrup formulation Active ingredient 0.2500 g Sorbitol Solution 1.5000 g Glycerol 1.0000 g Sodium Benzoate 0.0050 g Flavour 0.0125 ml Purified Water q.s. to 5.0 ml The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dissolved. The resulting solution is mixed with the glycerol and then made up to the required volume with the purified water. Suppository formulation mg/suppository Active ingredient (63µm)* 250 Hard Fat, BP (Witepsol H15 - Dynamit Nobel) 1770 2020 * The active ingredient is used as a powder wherein at least 90% of the particles are of 63µm diameter or less. One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaming Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250µm stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.02g aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.

Claims: A pyrimidine of formula (I): wherein, R 1 is N-methyl-piperazino; R 2 is amino; R 3 hydrogen, methyl, trifluoromethyl, benzylozymethyl, methoxymethyl or methyl-thiomethyl; R 4 is chloro; at least one of R 5 , R 6 and R 7 is chloro, and the remainder of R 5 , R 6 and R 7 are selected from hydrogen and chloro in the case of R 5 and R 7 , and from hydrogen, chloro and nitro in the case of R 6 except that R 6 is not hydrogen when R 1 is N-methylpiperazino, R 3 is hydrogen and each of R 5 and R 7 is chloro; R 8 is hydrogen; and pharmaceutically acceptable acid addition salts thereof. A compound according to claim 1, wherein R 5 , R 6 and R 7 are selected from hydrogen and chloro. A compound according to any one of the preceding claims wherein one or both of R 5 and R 7 are chloro. 2-(4-Methylpiperazin-1-yl)-4-amino-5-(2,3,5-trichlorophenyl)-6-trifluoromethylpyrimidine; 2-(4-Methylpiperazin-1-yl)-4-amino-5-(2,3,5-trichlorophenyl)-6-methylpyrimidine; 2-(4-Methylpiperazin-1-yl)-4-amino-5-(2,4-dichlorophenyl)pyrimidine; and pharmaceutically acceptable acid addition salts thereof. A pharmaceutically acceptable acid addition salt of a pyrimidine as claimed in any one of claims 1 to 4. A process for the preparation of a pyrimidine of formula (I) as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof, which process comprises reacting a compound of formula (II): wherein R 3 to R 4 are as defined in claim 1, L is a leaving group and Y is cyano, with a compound of formula (III) : wherein R 1 is as defined in claim 1, or a salt thereof; isolating the resulting pyrimidine of formula (I) as the free base or as a pharmaceutically acceptable acid addition salt thereof; and optionally converting the base into a pharmaceutically acceptable acid addition salt thereof or into another pyrimidine or formula (I) or a pharmaceutically acceptable acid addition salt thereof. A process according to claim 6, wherein L is C 1 -C 4 alkoxy. A process for the preparation of a pyrimidine of formula (I) as defined in claim 1, which process comprises reacting a compound of formula (V): wherein R 3 to R 8 are as defined in claim 1, Y is as defined in claim 6 and R 10 and R 11 are both alkyl or together form a group -(C(R) 2 ) n - where R is hydrogen or alkyl and n is an integer from 2 to 4, with a compound of formula (III) as defined in claim 6. A pharmaceutical formulation comprising a pyrimidine of formula (I) as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carrier therefor. A pharmaceutical formulation suitable for oral administration comprising a pyrimidine of formula (I) as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carrier therefor. Capsules or tablets suitable for oral administration, each containing a predetermined amount of a pyrimidine of formula (I) as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carrier therefor: A pharmaceutical formulation suitable for parenteral administration comprising a pyrimidine of formula (I) as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carrier therefor. A pharmaceutical formulation suitable for parenteral administration, which formulation is presented in unit-dose containers and comprises a pyrimidine of formula (I) as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable acid addition salt thereof and one or more acceptable carrier therefor.

Inventors: HYDE RICHARD MARTIN, LEACH MICHAEL JOHN, MILLER ALISTAIR AINSLIE, NOBBS MALCOLM STUART, HYDE, RICHARD MARTIN, LEACH, MICHAEL JOHN, MILLER, ALISTAIR AINSLIE, NOBBS, MALCOLM STUART
Applicants: WELLCOME FOUND, THE WELLCOME FOUNDATION LIMITED
Application year: 1989
Main classification: A61K31
IPC codes: A61K31, C07C255, C07D239